Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Nektar Shares Plunge After Pain Drug Study

By Pharmaceutical Processing | September 27, 2013

SAN FRANCISCO (AP) — Nektar Therapeutics shares sank in extended trading Thursday after the pharmaceutical maker said that a recent mid-stage study of its pain drug failed to meet its goal.

The San Francisco company’s drug, known as NKTR-181, is designed with a slow rate of entry into the brain, which the company says could make it less likely to be abused and could reduce other common side effects for similar drugs, such as sedation and respiratory depression.

Nektar said the study failed to meet its end goal because patients who made it to the randomized portion of the trial, in which they randomly received a placebo or the drug, did not show the expected increase in pain scores that was anticipated when they were put on the placebo.

The company said it remained committed to bringing the drug to patients suffering from chronic pain.

Nektar develops drugs for oncology, pain and other treatment areas.

Shares of the company lost 26 percent to $10.30 in after-hours trading. Its stock added 44 cents to close regular trading at $13.85, up 87 percent for the year.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE